Jacquie Chirgwin
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
Colleoni M, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber R, Coates A, Di Leo A, Regan M, Goldhirsch A, O'Reilly S, Müller B, Marth C, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas M, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, SOLE Investigators. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2017; 19:127-138.
Nov 17, 2017Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
Nov 17, 2017Lancet Oncol 2017; 19:127-138
Colleoni Marco, Di Lauro Vincenzo, Gombos Andrea, Ruhstaller Thomas, Burstein Harold, Ribi Karin, Bernhard Jürg, Viale Giuseppe, Maibach Rudolf, Rabaglio-Poretti Manuela, Gelber Richard D, Coates Alan S, Di Leo Angelo, Regan Meredith M, Goldhirsch Aron, O'Reilly Seamus, Müller Bettina, Marth Christian, Luo Weixiu, Karlsson Per, Chirgwin Jacquie, Aebi Stefan, Jerusalem Guy, Neven Patrick, Hitre Erika, Graas Marie-Pascale, Simoncini Edda, Kamby Claus, Thompson Alastair, Loibl Sibylle, Gavilá Joaquín, Kuroi Katsumasa, SOLE Investigators
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance For Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00
Colleoni M, Eniu A, Cagossi K, Rauch D, Chirgwin J, Gelber R, Regan M, Coates A, Price K, Viale G, Kralidis E, Tondini C, Gray K, Gelber S, Láng I, Thürlimann B, Gianni L, Abdi E, Gomez H, Linderholm B, Puglisi F, Goldhirsch A. Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance For Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. J Clin Oncol 2016
Jun 20, 2016Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance For Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00
Jun 20, 2016J Clin Oncol 2016
Colleoni Marco, Eniu Alexandru, Cagossi Katia, Rauch Daniel, Chirgwin Jacquie, Gelber Richard D, Regan Meredith M, Coates Alan S, Price Karen N, Viale Giuseppe, Kralidis Elena, Tondini Carlo, Gray Kathryn P, Gelber Shari, Láng István, Thürlimann Beat, Gianni Lorenzo, Abdi Ehtesham A, Gomez Henry L, Linderholm Barbro K, Puglisi Fabio, Goldhirsch Aron
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause
Chirgwin J, Coates A, Goldhirsch A, Regan M, Bonnefoi H, Ejlertsen B, Thürlimann B, Price K, Smith I, Sun Z, BIG 1-98 Collaborative and International Breast Cancer Study Groups. The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. Breast Cancer Res Treat 2011; 131:295-306.
Sep 4, 2011The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause
Sep 4, 2011Breast Cancer Res Treat 2011; 131:295-306
Chirgwin Jacquie, Coates Alan S, Goldhirsch Aron, Regan Meredith M, Bonnefoi Hervé, Ejlertsen Bent, Thürlimann Beat, Price Karen N, Smith Ian, Sun Zhuoxin, BIG 1-98 Collaborative and International Breast Cancer Study Groups
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
Colleoni M, Coates A, Gelber R, Price K, Wardley A, Pienkowski T, Chirgwin J, Smith I, Láng I, Paridaens R, Forbes J, Mauriac L, Mouridsen H, Thürlimann B, Regan M, Giobbie-Hurder A, Goldhirsch A. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 2011; 29:1117-24.
Feb 14, 2011Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
Feb 14, 2011J Clin Oncol 2011; 29:1117-24
Colleoni Marco, Coates Alan S, Gelber Richard D, Price Karen N, Wardley Andrew, Pienkowski Tadeusz, Chirgwin Jacquie, Smith Ian, Láng István, Paridaens Robert, Forbes John F, Mauriac Louis, Mouridsen Henning, Thürlimann Beat, Regan Meredith M, Giobbie-Hurder Anita, Goldhirsch Aron
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98
Coates A, Del Mastro L, Smith I, Chirgwin J, Nogaret J, Pienkowski T, Wardley A, Jakobsen E, Price K, Láng I, Colleoni M, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes J, Paridaens R, Castiglione-Gertsch M, Gelber R, Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. JCO 2007; 25:486-92.
Feb 10, 2007Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98
Feb 10, 2007JCO 2007; 25:486-92
Coates Alan S, Del Mastro Lucia, Smith Ian, Chirgwin Jacquie, Nogaret Jean-Marie, Pienkowski Tadeusz, Wardley Andrew, Jakobsen Erik H, Price Karen N, Láng István, Colleoni Marco, Keshaviah Aparna, Thürlimann Beat, Mouridsen Henning, Mauriac Louis, Forbes John F, Paridaens Robert, Castiglione-Gertsch Monica, Gelber Richard D, Goldhirsch Aron